Melzer Catharina, von der Ohe Juliane, Hass Ralf
Biochemistry and Tumor Biology Lab, Department of Obstetrics and Gynecology, Hannover Medical School, D-30625 Hannover, Germany.
Cancers (Basel). 2019 Feb 5;11(2):185. doi: 10.3390/cancers11020185.
Cellular communication within the tumor microenvironment enables important interactions between cancer cells and recruited adjacent populations including mesenchymal stroma/stem-like cells (MSC). These interactions were monitored in vivo following co-injection of GFP-labeled human MSC together with mcherry-labeled MDA-MB-231 breast cancer cells in NODscid mice. Within 14 days of tumor development the number of initially co-injected MSC had significantly declined and spontaneous formation of breast cancer/MSC hybrid cells was observed by the appearance of double fluorescing cells. This in vivo fusion displayed a rare event and occurred in less than 0.5% of the tumor cell population. Similar findings were observed in a parallel in vitro co-culture. Characterization of the new cell fusion products obtained after two consecutive flow cytometry cell sorting and single cell cloning revealed two populations, termed MDA-hyb3 and MDA-hyb4. The breast cancer fusion cells expressed both, GFP and mcherry and displayed more characteristics of the MDA-MB-231 cells than of the parental MSC. While little if any differences were determined in the proliferative capacity, a significant delay of MDA-hyb3 cells in tumor formation was observed when compared to the parental MDA-MB-231 cells. Moreover, MDA-hyb3 cells developed an altered pattern of distant organ metastases. These findings demonstrated dynamic tumor changes by in vivo and in vitro fusion with the development of new breast cancer hybrid cells carrying altered tumorigenic properties. Consequently, cancer cell fusion contributes to progressively increasing tumor heterogeneity which complicates a therapeutic regimen.
肿瘤微环境中的细胞通讯能够使癌细胞与包括间充质基质/干细胞样细胞(MSC)在内的募集到的相邻细胞群之间发生重要的相互作用。在NODscid小鼠中共同注射绿色荧光蛋白(GFP)标记的人MSC和mcherry标记的MDA-MB-231乳腺癌细胞后,对这些相互作用进行了体内监测。在肿瘤发展的14天内,最初共同注射的MSC数量显著下降,并且通过双荧光细胞的出现观察到乳腺癌/MSC杂交细胞的自发形成。这种体内融合是一种罕见事件,发生在不到0.5%的肿瘤细胞群体中。在平行的体外共培养中也观察到了类似的结果。对经过连续两次流式细胞术细胞分选和单细胞克隆后获得的新细胞融合产物进行表征,发现了两个群体,分别称为MDA-hyb3和MDA-hyb4。乳腺癌融合细胞同时表达GFP和mcherry,并且表现出更多MDA-MB-231细胞的特征,而不是亲代MSC的特征。虽然在增殖能力方面几乎没有差异,但与亲代MDA-MB-231细胞相比,观察到MDA-hyb3细胞在肿瘤形成方面有显著延迟。此外,MDA-hyb3细胞发生了远处器官转移模式的改变。这些发现证明了通过体内和体外融合以及携带改变的致瘤特性的新乳腺癌杂交细胞的发育,肿瘤发生了动态变化。因此,癌细胞融合导致肿瘤异质性逐渐增加,这使治疗方案变得复杂。